SUTRO BIOPHARMA, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
STRO$10.17-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
| Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||
| Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit) | |||||||||
| Balances at December 31, 2024 | 82,526,430 | $83 | $831,348 | $39 | $(786,869) | $44,601 | |||
| Issuance of common stock under Employee Stock Purchase Plan | 358,242 | — | 246 | — | — | 246 | |||
| Vesting of restricted stock units | 1,581,892 | 1 | (1) | — | — | — | |||
| Stock transaction associated with taxes withheld on restricted stock units | (117,523) | — | (180) | — | — | (180) | |||
| Stock-based compensation expense | — | — | 5,538 | — | — | 5,538 | |||
| Net unrealized loss on available-for-sale securities | — | — | — | (48) | — | (48) | |||
| Net loss | — | — | — | — | (75,968) | (75,968) | |||
| Balances at March 31, 2025 | 84,349,041 | $84 | $836,951 | $(9) | $(862,837) | $(25,811) | |||
| Reversal of common stock under Employee Stock Purchase Plan | (2,500) | — | — | — | — | ||||
| Vesting of restricted stock units | 436,245 | 1 | — | — | — | 1 | |||
| Stock transaction associated with taxes withheld on restricted stock units | (62,739) | — | (61) | — | — | (61) | |||
| Stock-based compensation expense | — | — | 5,263 | — | — | 5,263 | |||
| Net unrealized loss on available-for-sale securities | — | — | — | (4) | — | (4) | |||
| Net loss | — | — | — | — | (11,499) | (11,499) | |||
| Balances at June 30, 2025 | 84,720,047 | $85 | $842,153 | $(13) | $(874,336) | $(32,111) | |||
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 61,009,829 | $61 | $708,975 | $21 | $(559,408) | $149,649 |
| Exercise of common stock options | 23,748 | — | 117 | — | — | 117 |
| Issuance of common stock under Employee Stock Purchase Plan | 284,362 | — | 911 | — | — | 911 |
| Vesting of restricted stock units | 1,215,729 | 1 | (1) | — | — | — |
| Stock transaction associated with taxes withheld on restricted stock units | (77,122) | — | (374) | — | — | (374) |
| Stock-based compensation expense | — | — | 6,068 | — | — | 6,068 |
| Net unrealized loss on available-for-sale securities | — | — | — | (134) | — | (134) |
| Net loss | — | — | — | — | (58,213) | (58,213) |
| Balances at March 31, 2024 | 62,456,546 | $62 | $715,696 | $(113) | $(617,621) | $98,024 |
| Vesting of restricted stock units | 107,375 | — | — | — | — | — |
| Stock transaction associated with taxes withheld on restricted stock units | (8,474) | — | (37) | — | — | (37) |
| Stock-based compensation expense | — | — | 6,159 | — | — | 6,159 |
| Issuance of common stock in connection with underwritten offering, net of issuance costs of $3,474 | 14,478,764 | 15 | 71,512 | — | — | 71,527 |
| Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement | 4,827,373 | 5 | 24,566 | — | — | 24,571 |
| Net unrealized loss on available-for-sale securities | — | — | — | (50) | — | (50) |
| Net loss | — | — | — | — | (48,018) | (48,018) |
| Balances at June, 2024 | 81,861,584 | $82 | $817,896 | $(163) | $(665,639) | $152,176 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.